Skip navigation | ||
|
||
HOUSTON, Oct 25, 2004 (United Press International via COMTEX) -- University of Texas researchers have found a potential new protein indicator for prognosis of breast and ovarian cancer.
The marker is known as Rab25, and when researchers matched tumor samples to outcomes in about 100 patients diagnosed with either breast or ovarian cancer, they found a low level of Rab25 protein on a patient's cancer sample was associated with a better clinical outcome in both cancer types.
In the November, 2004 issue of the journal Nature Medicine, the researchers reported tumor cells that "over-express" the Rab25 protein are more aggressive and associated with poorer outcome.
Adding this protein to other known molecular markers of progression could contribute to a "highly predictive test of outcome in breast or ovarian cancer," said the study's lead investigator, Dr. Gordon Mills, a professor and chair of the Department of Molecular Therapeutics at the M. D. Anderson Cancer Center.
Related MedlinePlus Pages:
Home | Health Topics | Drug Information | Encyclopedia | Dictionary | News | Directories | Other Resources | |
Copyright | Privacy | Accessibility | Selection Guidelines U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health | Department of Health & Human Services |
Page last updated: 26 October 2004 |